Boston Scientific Adds Starbucks CFO and Takeda CEO to Board
Event summary
- Boston Scientific elected Cathy Smith (Starbucks CFO) and Christophe Weber (Takeda Pharmaceutical CEO) to its Board of Directors, effective February 18, 2026.
- Smith brings finance and operational expertise from roles at Starbucks, Nordstrom, Target, and Walmart.
- Weber offers global pharmaceutical leadership experience, having led Takeda since 2015.
- The additions follow the announced retirements of John Sununu and Yoshiaki Fujimori from the board.
The big picture
Boston Scientific's board refresh signals a push for diversified leadership, blending retail finance acumen with pharmaceutical expertise. The move aligns with broader trends in medtech governance, where cross-industry experience is increasingly valued to navigate complex regulatory and market landscapes. The additions come as the company seeks to balance innovation with disciplined growth in a competitive sector.
What we're watching
- Strategic Realignment
- How Smith's retail and finance expertise will influence Boston Scientific's operational strategy.
- Pharma Synergies
- Whether Weber's pharmaceutical background will drive deeper industry collaborations.
- Board Dynamics
- The impact of the new directors' tenures on governance and long-term decision-making.